Literature DB >> 18248271

Applying heart failure guidelines to adult congenital heart disease patients.

Robert E Shaddy1, Gary Webb.   

Abstract

There is a growing population of adult patients with congenital heart defects in the developed world. Most have been repaired, but few have been cured. Many have myocardial dysfunction. Most have exercise intolerance. Some have heart failure. As a group, they show neurohormonal activation similar to that seen in an adult heart failure population with acquired heart disease. Currently, the patients at greatest risk of heart failure are those without a systemic left ventricle, such as Mustard and Senning repairs of transposition of the great arteries (TGA), congenitally corrected TGA, and patients who have had a Fontan procedure. Exercise intolerance may predict hospitalization and death in such patients. For those patients with systemic left ventricles, it would seem reasonable to use the heart failure guidelines developed for patients with acquired heart disease. For those patients without a systemic left ventricle (e.g., a systemic right ventricle or single ventricle), there is currently no foundation for evidence-based therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248271     DOI: 10.1586/14779072.6.2.165

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  12 in total

1.  Clinical research priorities in adult congenital heart disease.

Authors:  Timothy Cotts; Paul Khairy; Alexander R Opotowsky; Anitha S John; Anne Marie Valente; Ali N Zaidi; Stephen C Cook; Jamil Aboulhosn; Jennifer Grando Ting; Michelle Gurvitz; Michael J Landzberg; Amy Verstappen; Joseph Kay; Michael Earing; Wayne Franklin; Brian Kogon; Craig S Broberg
Journal:  Int J Cardiol       Date:  2013-12-24       Impact factor: 4.164

Review 2.  Genetic testing in congenital heart disease: A clinical approach.

Authors:  Marie A Chaix; Gregor Andelfinger; Paul Khairy
Journal:  World J Cardiol       Date:  2016-02-26

Review 3.  Heart failure in congenital heart disease: the role of genes and hemodynamics.

Authors:  Rachel D Vanderlaan; Christopher A Caldarone; Peter H Backx
Journal:  Pflugers Arch       Date:  2014-02-01       Impact factor: 3.657

4.  Managing heart failure in adults with congenital heart disease.

Authors:  Thomas D Ryan; John L Jefferies; Ivan Wilmot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-02

5.  The Fontan pathway: What's down the road?

Authors:  Sachin Khambadkone
Journal:  Ann Pediatr Cardiol       Date:  2008-07

6.  Implantation of total artificial heart in congenital heart disease.

Authors:  Iki Adachi; David S L Morales
Journal:  J Vis Exp       Date:  2014-07-18       Impact factor: 1.355

7.  Angiopoietin-2 in adults with congenital heart disease and heart failure.

Authors:  Alexander Lukasz; Gernot Beutel; Philipp Kümpers; Agnieszka Denecke; Mechthild Westhoff-Bleck; Bernhard Schieffer; Johann Bauersachs; Jan T Kielstein; Oktay Tutarel
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Asymmetrical dimethylarginine--more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease.

Authors:  Oktay Tutarel; Agnieszka Denecke; Stefanie M Bode-Böger; Jens Martens-Lobenhoffer; Svjetlana Lovric; Johann Bauersachs; Bernhard Schieffer; Mechthild Westhoff-Bleck; Jan T Kielstein
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

9.  Unscheduled hospitalization in adults with congenital heart disease.

Authors:  Jun Negishi; Hideo Ohuchi; Kenji Yasuda; Aya Miyazaki; Nakanishi Norifumi; Osamu Yamada
Journal:  Korean Circ J       Date:  2015-01-26       Impact factor: 3.243

10.  Targeted metabolomic analysis of serum phospholipid and acylcarnitine in the adult Fontan patient with a dominant left ventricle.

Authors:  Miriam Michel; Karl-Otto Dubowy; Manuela Zlamy; Daniela Karall; Mark Gordian Adam; Andreas Entenmann; Markus Andreas Keller; Jakob Koch; Irena Odri Komazec; Ralf Geiger; Christina Salvador; Christian Niederwanger; Udo Müller; Sabine Scholl-Bürgi; Kai Thorsten Laser
Journal:  Ther Adv Chronic Dis       Date:  2020-04-27       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.